Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy

International Ophthalmology

Volumn 29, Issue 4, 2009, Pages 267-269

  Koseoglu, Selim T ^a   Harmatz, Paul ^a   Turbeville, Sean ^b   Nicely, Helen ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Galsulfase; Glycosominoglycans; Mucopolysaccharidosis VI; N Acetylgalactosamine 4 sulfatase; Papilledema

Indexed keywords

CREATININE; GALSULFASE; GLYCOSAMINOGLYCAN; PLACEBO;

ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; CORNEA DISEASE; CREATININE URINE LEVEL; DRUG EFFICACY; ECTROPION; ENZYME REPLACEMENT; EYE EXAMINATION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAROTEAUX LAMY SYNDROME; OPTIC NERVE ATROPHY; PAPILLEDEMA; SCHOOL CHILD; TREATMENT DURATION; VISUAL ACUITY;

CHILD; FEMALE; HUMANS; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; PAPILLEDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REMISSION INDUCTION; VISUAL ACUITY;

EID: 68249135872     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-008-9213-7     Document Type: Article

References (2)

1. Swiedler SJ, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A 134(2):144-150
2. Byers S, Crawley AC, Brumfield LK, Nuttall JD, Hopwood JJ (2000) Enzyme-replacement therapy in a feline model of MPS VI: Modification of enzyme structure and dose frequency. Pediatr Res 47(6):743-749